Ribomic Inc.
Research Ribomic Inc. (4591.T) on Bullrun: market cap JPY 3.85B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4591.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 3.85B
- Financial periodFY2026
- RevenueJPY 3.00M
- Revenue growth42.4%
- Net income-JPY 1.15B
- Free cash flow-JPY 1.12B
Valuation Snapshot
latest market cap is JPY 3.85B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 3.00M | -JPY 1.15B | -JPY 1.12B | n/a | -23.07 | JPY 1.93B | n/a | JPY 2.84B |
| FY2025 | JPY 2.11M | -JPY 1.02B | -JPY 1.03B | n/a | -25.21 | JPY 1.84B | n/a | JPY 3.04B |
| FY2024 | JPY 0 | -JPY 1.02B | -JPY 955.48M | n/a | -28.7 | JPY 2.10B | n/a | JPY 3.39B |
| FY2023 | JPY 65.97M | -JPY 1.65B | -JPY 1.73B | n/a | -53.14 | JPY 2.83B | n/a | JPY 4.38B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 3.85B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About Ribomic Inc.
Ribomic Inc. engages in the discovery and development of pharmaceutical compounds using RNA aptamers in Japan and Europe. The company develops RBM-007, which is in Phase III clinical trial for the treatment of achondroplasia; Phase II clinical trial for the treatment of wet age-related macular degeneration; and pre-clinical trial for the treatment of diabetic macular edema.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Ribomic Inc.'s market cap?
Ribomic Inc.'s market capitalization is JPY 3.85B.
What does Ribomic Inc. do?
Ribomic Inc. engages in the discovery and development of pharmaceutical compounds using RNA aptamers in Japan and Europe. The company develops RBM-007, which is in Phase III clinical trial for the treatment of achondroplasia; Phase II clinical trial for the treatment of wet age-related macular degeneration; and pre-clinical trial for the treatment of diabetic macular edema.